Document:

Exhibit 10.1

Exhibit 10.1

FARMERS NATIONAL BANC CORP.

CASH INCENTIVE PLAN

Amended and Restated June, 2011

	I.	 	Term of Plan

The Farmers National Banc Corp. Cash Incentive Plan (the “Plan”) is effective as of January 1,
2011, and will remain in effect until revised or terminated by the recommendation of the
Compensation Committee and approved by the Board of Directors of Farmers National Banc Corp.
(“Farmers”).

	II.	 	Objective

Farmers is making available to eligible executives and employees of Farmers and its subsidiaries,
through this Plan, compensation designed to foster superior financial results for Farmers by
providing an equitable corporate-wide incentive that awards individual and team effort to achieve
specified performance objectives. The objectives of the Plan are: (1) to foster superior financial
results for Farmers, producing a financial benefit to Farmers shareholders; (2) to motivate and
reward executives toward superior financial performance; (3) attracting and retaining skilled
executives and employees upon whose judgment, interest and special efforts the successful conduct
of Farmers’ business is largely dependent; and (5) appropriately balance and manage risk to promote
the overall safety and soundness of Farmers.

	III.	 	Participants

Full-time and part-time, regular, non-commissioned-based associates and executives of Farmers and
its subsidiaries and affiliates are generally eligible to participate in the Plan. Participation
determinations regarding executive officers (“Executive Participants”) shall be established by the
Compensation Committee in its sole discretion. Participation determinations regarding associates
and other non-executive personnel (“Non-Executive Participants” and together with Executive
Participants, “Participants” ) shall be established by the Senior Management Committee (as defined
hereafter).

	IV.	 	Opportunity Levels

Participant opportunity levels (as a percentage of base salary) shall be determined on an annual
basis by the Compensation Committee with respect to Executive Participants or the Senior Management
Committee with respect to Non-Executive Participants, as the case may be, and will generally be
determined by the Participant’s title and functional responsibility as well as other
considerations, including, but not limited to, external market competitiveness, retention
considerations as well as corporate and individual performance.

 

 

 

	V.	 	Performance Goals and Metrics

In order to receive an award under the Plan, the Participant and/or Farmers must attain specified
performance metrics in applicable performance goal categories. Performance goals may be set in
any of following five general categories with performance metrics and targets set forth in
individual scorecards developed for each Participant: (i) corporate goals; (ii) district goals;
(iii) branch goals; (iv) group goals; and (v) individual goals.

Each year in the first quarter of the calendar year (or, for 2011, upon adoption of the Plan) the
Compensation Committee with respect to Executive Participants or the Senior Management Committee
with respect to Non-Executive Participants, as the case may be, shall determine individual
performance goals and metrics for each Participant. For purposes of determining performance metrics
for each Participant, the Compensation Committee with respect to Executive Participants and the
Senior Management Committee with respect to Non-Executive Participants, as the case may be, shall
establish metrics relating to one or several of the following corporate performance measures:

	1.	 	Revenue;

	 
	2.	 	Net earnings or net income (before or after taxes);

	 
	3.	 	Earnings per share;

	 
	4.	 	Deposit or asset growth;

	 
	5.	 	Net operating income;

	 
	6.	 	Return measures (including return on assets and equity);

	 
	7.	 	Fee income;

	 
	8.	 	Earnings before or after taxes, interest, depreciation and/or amortization;

	 
	9.	 	Interest spread;

	 
	10.	 	Productivity ratios;

	 
	11.	 	Share price (including, but not limited to, growth measures and total shareholder return);

	 
	12.	 	Expense targets;

	 
	13.	 	Credit quality;

	 
	14.	 	Efficiency ratio;

	 
	15.	 	Market share;

	 
	16.	 	Customer satisfaction;

	 
	17.	 	NIACC (net income after cost of capital);

	 
	18.	 	Texas ratio; and

	 
	19.	 	Strategic objectives (including, branding, mergers and acquisitions, succession management,
dynamic market response, new product development, expense reduction initiatives, risk management
and regulatory compliance).

	VI.	 	Goal Achievement

For purposes of determining goal achievement, the Compensation Committee with respect to Executive
Participants and the Senior Management Committee with respect to Non-Executive Participants, as the
case may be, shall (i) establish the performance period for determining goal achievement for each
Participant; (ii) establish threshold, target and maximum performance goals for each performance
metric; and (iii) determine the respective weighting for performance metrics for each Participant.
The mix and weighting of the performance metrics established for determining awards need not be
the same for all Participants or any group of Participants.

 

2

 

A Participant’s final award will be based on achievement of the established corporate and
individual performance metrics, subject to the approval of the Compensation Committee with respect
to Executive Participants or the Senior Management Committee with respect to Non-Executive
Participants, as the case may be. Awards for results achieved between specified performance levels
will be paid out on an interpolated basis. Notwithstanding anything else in the Plan, in their sole
discretion, the Compensation Committee with respect to Executive Participants or the Senior
Management Committee with respect to Non-Executive Participants, as the case may be, may adjust any
one or more award amounts before or after the applicable performance period, change goals or waive
any requirements for awards pursuant to the Plan.

For purpose of determining the amount of any award, the base salary utilized for award calculations
will be the annualized base salary of the Participant on the last day of the applicable calendar
year, adjusted to reflect the Participant’s tenure with the Company during the year.

	VII.	 	Payments

Subject to applicable withholding, payments under the Plan will be made as soon as reasonably
practicable following the completion of the performance period and following approval by the
Compensation Committee with respect to Executive Participants or Senior Management Committee with
respect to Non-Executive Participants, as the case may be, for awards to Participants. The accrual
for Plan incentive payments will be established in accordance with generally accepted accounting
principles.

	VIII.	 	NEWLY HIRED, TRANSFERRED, PROMOTED AND TERMINATED PARTICIPANTS

If a Participant is transferred or promoted or becomes totally disabled in accordance with the
Company’s long-term disability plan before the last day of the calendar year, the Participant will
be eligible to receive payment under the Plan only if: (1) the Participant is employed on the last
day of the calendar year; (2) the Participant remains employed through the payment date; and (3)
the stated threshold goals have been achieved by the last day of the performance period, as such
goals may be revised for the individual based upon a change in position. Payments will be prorated
based upon the tenure of the Participant in the eligible position. Newly hired eligible Plan
Participants may receive a prorated incentive payout based on their tenure or a predetermined
payout amount agreed upon as part of their initial employment terms.

If the Participant’s employment is terminated before the payment date for any reason other than
retirement, the Participant will not be eligible for any payment under the Plan regardless of
employment status on the last day of the calendar year.

If a Participant dies before the end of the calendar year, neither the Participant nor their estate
will be eligible to receive any payment under the Plan. If a Participant dies after the end of the
calendar year, but before the payment date, the Participant, through their estate, will be eligible
to receive payment of an award amount under the Plan.

 

3

 

If a Participant retires (as retirement is defined under any Farmers benefit plan providing for the
earliest possible retirement) effective before the end of the calendar year, the Participant will
not be entitled to payment under the Plan. If the Participant retires effective at any time after
the end of the calendar year, but before the payment date, the retiring Participant will be
entitled to payment in accordance with the terms of the Plan.

At the discretion of the Compensation Committee with respect to Executive Participants or the
Senior Management Committee with respect to Non-Executive Participants, as the case may be,
Participants may be eligible to participate in the Plan during a Plan year in which he or she takes
a leave of absence.

Farmers reserves the right to withhold or decrease payments to any Participant under the Plan based
on a Participant’s violation of any of Farmers’ policies and procedures or failure to achieve an
adequate annual performance evaluation.

	IX.	 	OTHER EMPLOYEE BENEFITS

Benefits to Participants under other benefit plans will not be affected by payments under this Plan
to the extent benefits under the other plans are based upon base salary, but will be affected by
payments under this Plan to the extent benefits under the other plans are based upon Form W-2
earnings. Farmers retains the right to amend, cancel or change any other benefit plans. Nothing in
this Plan shall change the normal employee/employer relationship or be interpreted as a guarantee
of continued employment to any Participant and no award payment under this Plan shall be construed
as an indication of over-all job performance.

	X.	 	SENIOR MANAGEMENT COMMITTEE

For purposes of Non-Executive Participant Plan administration, the Senior Management Committee
shall consist of the following persons: (1) Chief Executive Officer; (2) Chief Financial Officer;
(3) Director of Retail; (4) Director of Human Resources; and (5) Chief Credit Officer.

	XI.	 	AMENDMENT AND ADMINISTRATION OF THE PLAN

The Plan may be terminated or amended by the recommendation of the Compensation Committee, subject
to the approval of the Board of Directors. Any question of interpretation of the Plan will be
determined by the Compensation Committee and its determinations are final, binding and
non-appealable. Notwithstanding anything else in the Plan, in their sole discretion, the
Compensation Committee with respect to Executive Participants or the Senior Management Committee
with respect to Non-Executive Participants, as the case may be, may adjust any one or more award
amounts before or after the applicable performance period, change goals or waive any requirements
for awards pursuant to the Plan.

 

4exv10w3w2

EXHIBIT 10.3.2

*Certain portions of this exhibit have been omitted pursuant to a request for confidential treatment

which has been filed separately with the SEC.

THIRD AMENDMENT TO MANUFACTURING AND SUPPLY AGREEMENT

FOR N-ACETYLCYSTEINE

     THIS THIRD AMENDMENT (the “Third Amendment”) to that certain Manufacturing and Supply
Agreement for N-Acetylcysteine, dated as of January 15, 2002 (the “Original Agreement”), as
modified by that certain Novation Agreement, dated as of January 27, 2006 (the “Novation
Agreement”), as amended by that certain First Amendment to Manufacturing and Supply Agreement
for N-Acetylcyesteine dated as of November 16, 2006 (the “First Amendment”) and as amended
by that certain Second Amendment to Manufacturing and Supply Agreement for N-Acetylcyesteine dated
as of March 25, 2008 (the “Second Amendment”) is entered into by and between CUMBERLAND
PHARMACEUTICALS INC., a corporation organized and existing under the laws of Tennessee, United
States (“CUMBERLAND”), and BIONICHE TEORANTA, a corporation organized and existing under
the laws of Ireland (“BIONICHE”), and is effective as of April 25, 2011 (The Original
Agreement, the Novation Agreement, the First Amendment, the Second Amendment and the Third
Amendment are collectively referred to herein as the “Agreement”). Capitalized terms used
but not defined in this Third Amendment shall have the meanings that are set forth in the
Agreement.

WITNESSETH:

               WHEREAS, BIONICHE is the assignee under the Agreement of BIONICHE PHARMA GROUP LIMITED, an
Affiliate thereof.

               NOW, THEREFORE, in consideration of the mutual covenants, agreements, representation and
warranties contained herein, and for other good and valuable consideration, the receipt of which is
hereby acknowledged, the parties hereto hereby agree as follows:

	 	1.	 	Section 2.1, is amended to remove the words “all of” from second line of
the first sentence.

	 
	 	2.	 	Paragraph 3.1 is amended and restated in its entirety as follows:

	 
	 	 	 	This Agreement shall commence on the date first above written and will continue
until April 15, 2014, unless sooner terminated pursuant to Paragraph 3.2 hereof
or extended pursuant to this Paragraph 3.1. The Agreement may be extended for
two (2) year upon the mutual written consent of both parties; otherwise, the
Agreement shall expire on such date in accordance with its terms.

	 
	 	3.	 	Paragraph 3.2 is amended by inserting the following Subparagraph 3.2(e)
after Subparagraph 3.2(d):

1

 

	 	 	 	In the event that the parties mutually agree to extend the Agreement after
April 15, 2014, either party may terminate the Agreement upon twelve (12)
months prior written notice to the other Party.

	 
	 	4.	 	Paragraph 5.6(b) is deleted in its entirety. Subparagraphs 5.6(c) and (d)
are re-lettered as 5.6(b) and (c), respectively; and Subparagraph 5.6(d)
(re-lettered 5.6(c)) is amended and restated in its entirety as follows:

	 
	 	 	 	(c) Notwithstanding the foregoing, CUMBERLAND may establish supply arrangements
with third parties.

	 
	 	5.	 	Paragraph 5.7 is deleted in its entirety and restated in its entirety as
follows:

	 
	 	 	 	“Minimum Purchase Quantities: CUMBERLAND shall be required to purchase [***]
batches annually of the Dug Product being sold in the Territory from BIONICHE.
In the event CUMBERLAND is required to procure Drug Product from other sources
in accordance with Paragraph 2.7, the minimum annual purchase obligation set
forth in this Paragraph 5.7 shall be decreased by the quantity that BIONICHE
failed to deliver hereunder.

	 
	 	6.	 	In the Section entitled “Pricing” in SCHEDULE I, the first paragraph is
hereby amended and restated as follows:

	 
	 	 	 	Pursuant to Paragraph 2.10(a) of the Original Agreement, the price to be paid
by CUMBERLAND to BIONICHE for the Drug Products ordered from BIONICHE is as
follows:

	 	 	 	 	 
	N-acetylcysteine 30 ml

	 	US
	 	$[***] per vial for the first [***] batches of
product received annually
	 
	 	 	 	 
	N-acetylcysteine 30 ml

	 	US
	 	$[***] for subsequent batches of product
received annually

	 	7.	 	In the Section entitled “Pricing” in SCHEDULE I, the second paragraph is
hereby amended and restated as follows:

	 
	 	 	 	Beginning on January 1, 2012, BIONICHE shall have the annual right to increase
price set forth above, provided, however, that such annual price increase shall
not exceed the annual percentage increase for the most recent twelve (12) month
period for which information is available in the Product Price Index,
Pharmaceutical Preparations, Ethical (Prescription), commodity code PCU325412,
issued by the Bureau of Labor Statistics, U.S. Department of Labor.

	 
	 	8.	 	In the Section entitled “Pricing” in SCHEDULE I, the following language
will be added to the fourth paragraph as follows:

	 
	 	 	 	CUMBERLAND will have no obligation to pay any royalties that would
accrue after January 23, 2011 to BIONICHE on any purchases of product
manufactured by BIONICHE or by a third party contractor. Provided,

2

 

	 	 	 	however, CUMBERLAND shall pay all royalties that would accrue on or
before January 23, 2011 to BIONICHE on any purchases of product
manufactured by BIONICHE or by a third party contractor.

	 
	 	9.	 	In the Section entitled “Territory” in SCHEDULE III, the language
shall be amended and restated as “Worldwide”.

	 
	 	10.	 	Miscellaneous.

	 
	 	 	 	     (a) Authorization. Each party to this Third Amendment hereby
represents and warrants that the execution, delivery and performance of this
Third Amendment is within the powers of such party and has been duly authorized
by the party, is in accordance with all applicable laws and regulations, and
this Third Amendment constitutes the valid and enforceable obligation of each
party in accordance with its terms.

	 
	 	 	 	     (b) Effect of Third Amendment. Each party acknowledges that this
Third Amendment constitutes a written instrument as contemplated by Paragraph
11.2 of the Agreement. Except as specifically amended above, the Agreement
shall remain in full force and effect, and is hereby ratified and confirmed.

	 
	 	 	 	     (c) Counterparts. This Third Amendment may be executed in any
number of counterparts, each of which may be executed by only one of the
parties hereto, and each of which shall be enforceable against the party
actually executing such counterpart, and all of which shall together constitute
one instrument.

	 
	 	 	 	     (d) Titles and Subtitles. The titles and subtitles used in this
Third Amendment are used for convenience only and are not to be considered in
construing or interpreting this Third Amendment.

	 
	 	 	 	     (e) Governing Law and Dispute Resolution. This Third Amendment
shall be construed in accordance with the laws of the State of New York without
regard to applicable conflicts of laws provisions and any dispute, controversy,
or claim arising out of or relating to this Third Amendment shall be governed
by the provisions of Paragraph 11.7 of the Agreement.

	 
	 	 	 	     (f) Severability. Should any part of this Third Amendment be
invalid or unenforceable, such invalidity or unenforceability shall not affect
the validity and enforceability of the remaining portion.

3

 

IN WITNESS WHEREOF, each of the undersigned has caused this Third Amendment to be executed
effective as of the date first above written.

	 	 	 	 	 
	 

	 	CUMBERLAND:
	 
	 	 	 	 
	 

	 	CUMBERLAND PHARMACEUTICALS INC.
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	By:
	 	/s/ A.J. Kazimi
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	Name:
	 	A. J. Kazimi

	 
	 	 	 	 
	 

	 	Title:
	 	Chief Executive Officer
	 
	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	BIONICHE:
	 
	 	 	 	 
	 

	 	BIONICHE TEORANTA
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	By:
	 	/s/ Damien Kelly
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	Name:
	 	Damien Kelly
	 
	 	 	 	 
	 

	 	Title:
	 	Chief Financial Officer

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}]]